Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature

Bosn J Basic Med Sci. 2022 Apr 1;22(2):300-301. doi: 10.17305/bjbms.2021.6419.

Authors

Zhe-Sheng Chen¹, Dong-Hua Yang²

Affiliations

¹ Department of Pharmaceutical Sciences, St. John's University, New York, USA.
² Department of Pharmaceutical Sciences, St. John'sUniversity, New York, USA; Institute for Biotechnology, St. John's University, New York, USA.

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Combined Modality Therapy
Humans
Killer Cells, Natural
Lymphoma, T-Cell*
Polymorphism, Single Nucleotide*